{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:36:33Z","timestamp":1777588593025,"version":"3.51.4"},"reference-count":80,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are increasingly used in patients with type 2 diabetes, chronic kidney disease, and heart failure. However, their safety and efficacy in patients with congenital or surgically altered urogenital anatomy remains underexplored. Methods: We conducted a narrative review of current evidence regarding the use of SGLT2i in patients with urinary tract malformations, urinary diversions, and functional voiding disorders. Key risks, clinical considerations, and management strategies were synthesized from the existing literature and case reports. Results: Patients with benign prostatic hyperplasia, vesicoureteral reflux, neurogenic bladder, nephrostomies, and ileal conduits may face increased risks of urinary tract infections, fungal colonization, and therapy-related complications due to persistent glycosuria and altered urinary flow. Nevertheless, these patients may still benefit from SGLT2i\u2019s systemic renal and cardiovascular effects. Individualized risk assessment, close monitoring, and multidisciplinary management are essential. Conclusions: Patients with urological abnormalities represent a high-risk but potentially high-reward population for SGLT2i therapy. A cautious, tailored approach is necessary, and future dedicated research is urgently needed to better guide clinical practice.<\/jats:p>","DOI":"10.3390\/medicina61050921","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T08:41:12Z","timestamp":1747730472000},"page":"921","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["SGLT2 Inhibitors in Patients with Urogenital Malformations and Urinary Diversions: Risks, Benefits, and Clinical Considerations"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6057-9858","authenticated-orcid":false,"given":"Mohammed","family":"Abdulrasak","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences, Lund University, 22100 Malmo, Sweden"},{"name":"Department of Gastroenterology and Nutrition, Skane University Hospital, 20502 Malmo, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Someili","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9353-6520","authenticated-orcid":false,"given":"Mostafa","family":"Mohrag","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","first-page":"117","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"Herrington","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40256-024-00673-1","article-title":"SGLT2 Inhibitors and How They Work beyond the Glucosuric Effect. State of the Art","volume":"24","year":"2024","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e031805","DOI":"10.1161\/JAHA.123.031805","article-title":"Comparison of Effectiveness among Different Sodium-Glucose Cotransoporter-2 Inhibitors According to Underlying Conditions: A Network Meta-Analysis of Randomized Controlled Trials","volume":"13","author":"Kani","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/dom.15696","article-title":"Key Results from Observational Studies and Real-world Evidence of Sodium-glucose Cotransporter-2 Inhibitor Effectiveness and Safety in Reducing Cardio-renal Risk","volume":"26","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Hunsuwan, S., Boongird, S., Ingsathit, A., Ponthongmak, W., Unwanatham, N., McKay, G.J., Attia, J., and Thakkinstian, A. (2025). Real-World Effectiveness and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Chronic Kidney Disease. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-86172-y"},{"key":"ref_10","first-page":"032","article-title":"Rehospitalisation Rates of Heart Failure Patients Treated with SGLT2 Inhibitors as an Inpatient versus Post-Discharge","volume":"31","author":"Yick","year":"2024","journal-title":"Br. J. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e032296","DOI":"10.1161\/JAHA.123.032296","article-title":"Time to SGLT2 Inhibitors Initiation in Patients with Heart Failure","volume":"13","author":"Moon","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jacc.2017.11.019","article-title":"Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy","volume":"71","author":"Marwick","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_13","first-page":"100988","article-title":"Estimating the Population-Level Impacts of Improved Uptake of SGLT2 Inhibitors in Patients with Chronic Kidney Disease: A Cross-Sectional Observational Study Using Routinely Collected Australian Primary Care Data","volume":"43","author":"Neuen","year":"2023","journal-title":"Lancet Reg. Health-West. Pac."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of Diabetes on the Effects of Sodium Glucose Co-Transporter-2 Inhibitors on Kidney Outcomes: Collaborative Meta-Analysis of Large Placebo-Controlled Trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"ref_15","first-page":"e080925","article-title":"SGLT-2 Inhibitors and Mortality among Patients with Heart Failure with Reduced Ejection Fraction: Linked Database Study","volume":"387","author":"Mkoma","year":"2024","journal-title":"BMJ"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e18245","DOI":"10.1097\/MD.0000000000018245","article-title":"Effects of SGLT2 Inhibitors on Cardiovascular Outcomes and Mortality in Type 2 Diabetes","volume":"98","author":"Zou","year":"2019","journal-title":"Medicine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","article-title":"Executive Summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: An Update Based on Rapidly Emerging New Evidence","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Roddick, A.J., Wonnacott, A., Webb, D., Watt, A., Watson, M.A., Staplin, N., Riding, A., Lioudaki, E., Kuverji, A., and Kossi, M.E. (2023). UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE. BMC Nephrol., 24.","DOI":"10.1186\/s12882-023-03339-3"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Xu, J., Sun, A., Yang, Y., Shi, Y., Su, J., Eadon, M.T., and Zhang, P. (2025). Risk of Urinary Tract Infections with SGLT-2 Inhibitors in Subpopulations with Abnormal Genitourinary Pathology. Clin. J. Am. Soc. Nephrol.","DOI":"10.2215\/CJN.0000000687"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M18-3136","article-title":"Sodium\u2013Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections","volume":"171","author":"Dave","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"ref_22","first-page":"100226","article-title":"Metabolic and Microbial Crossroads: Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections in (Asian) Diabetes Care","volume":"15","author":"Carpenter","year":"2025","journal-title":"Health Sci. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1007\/s00467-023-05899-w","article-title":"Congenital Anomalies of the Kidney and Urinary Tract: Defining Risk Factors of Disease Progression and Determinants of Outcomes","volume":"38","author":"Walawender","year":"2023","journal-title":"Pediatr. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Zheng, S., Carugo, D., Clavica, F., Mosayyebi, A., and Waters, S. (2022). Flow Dynamics in Stented Ureter. Urinary Stents, Springer.","DOI":"10.1007\/978-3-031-04484-7_13"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2042098621997703","DOI":"10.1177\/2042098621997703","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors and Risk for Genitourinary Infections in Older Adults with Type 2 Diabetes","volume":"12","author":"Varshney","year":"2021","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40262-015-0264-4","article-title":"Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease","volume":"54","author":"Scheen","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13098-023-01092-z","article-title":"Efficacy and Safety Evaluation of SGLT2i on Blood Pressure Control in Patients with Type 2 Diabetes and Hypertension: A New Meta-Analysis","volume":"15","author":"Zhang","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41440-023-01543-0","article-title":"Who Benefits from the Blood Pressure-Lowering Effects of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease?\u2014Obese or Non-Obese?","volume":"47","author":"Shiina","year":"2023","journal-title":"Hypertens. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"771","DOI":"10.34067\/KID.0000000000000425","article-title":"SGLT2 Inhibitors and Kidney Protection: Mechanisms beyond Tubuloglomerular Feedback","volume":"5","author":"Upadhyay","year":"2024","journal-title":"Kidney360"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ckj\/sfy090","article-title":"The Potential for Improving Cardio-Renal Outcomes by Sodium-Glucose Co-Transporter-2 Inhibition in People with Chronic Kidney Disease: A Rationale for the EMPA-KIDNEY Study","volume":"11","author":"Herrington","year":"2018","journal-title":"Clin. Kidney J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.14744\/cpr.2024.60933","article-title":"Urinary Tract Infections and Fungal Infections Associated with SGLT-2 Inhibitors and Metformin Combination: A Real-World Study from 2013 to 2023 Based on FAERS Database","volume":"46","author":"Aksoyalp","year":"2024","journal-title":"J. Clin. Pract. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/dom.13959","article-title":"A Hypothesis for Why Sodium Glucose Co-transporter 2 Inhibitors Have Been Found to Cause Genital Infection, but Not Urinary Tract Infection","volume":"22","author":"Fralick","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jacc.2024.01.040","article-title":"Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors","volume":"83","author":"Kittipibul","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/DMSO.S51792","article-title":"Urinary Tract Infections in Patients with Type 2 Diabetes Mellitus: Review of Prevalence, Diagnosis, and Management","volume":"8","author":"Saliba","year":"2015","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"751","DOI":"10.34067\/KID.0000472021","article-title":"Lower Urinary Tract Symptoms Should Be Queried When Initiating Sodium Glucose Co-Transporter 2 Inhibitors","volume":"2","author":"Krepostman","year":"2021","journal-title":"Kidney360"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.urology.2024.06.036","article-title":"Associations between Sodium-Glucose Co-Transporter 2 Inhibitors and Urologic Diseases: Implications for Lower Urinary Tract Symptoms from a Multi-State Health System Analysis","volume":"192","author":"Roth","year":"2024","journal-title":"Urology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1097\/01.JU.0001008772.30001.48.04","article-title":"PD12-04 SGLT2 Inhibitors Associate with Overactive Bladder Symptoms","volume":"211","author":"Mershon","year":"2024","journal-title":"J. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/pdi.2160","article-title":"Changes in Overactive Bladder Symptoms after Sodium Glucose Cotransporter-2 Inhibitor Administration to Patients with Type 2 Diabetes","volume":"35","author":"Shikuma","year":"2018","journal-title":"Pract. Diabetes"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Saijo, Y., Okada, H., Hata, S., Nakajima, H., Kitagawa, N., Okamura, T., Osaka, T., Kitagawa, N., Majima, S., and Senmaru, T. (2023). Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12226993"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.mayocp.2024.11.024","article-title":"Benign Prostatic Hyperplasia Increases Long-Term Chronic Kidney Disease Risk","volume":"100","author":"Ouyang","year":"2025","journal-title":"Mayo Clin. Proc."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/j.1523-1755.2005.00344.x","article-title":"The Association between Benign Prostatic Hyperplasia and Chronic Kidney Disease in Community-Dwelling Men","volume":"67","author":"Rule","year":"2005","journal-title":"Kidney Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11934-009-0044-5","article-title":"Diabetes and Benign Prostatic Hyperplasia: Emerging Clinical Connections","volume":"10","author":"Sarma","year":"2009","journal-title":"Curr. Urol. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.jiac.2021.06.006","article-title":"Complicated Urinary Tract Infection in Patients with Benign Prostatic Hyperplasia","volume":"27","author":"Choi","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_45","unstructured":"EAU Guidelines (2024). Presented at the EAU Annual Congress, Paris, France, 5\u20138 April 2024, EAU Guidelines Office. Available online: https:\/\/uroweb.org\/guidelines."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1177\/08971900241229107","article-title":"Risk of Urinary Infections in Veterans on Empagliflozin with Concurrent Catheter Use","volume":"37","author":"Hopper","year":"2024","journal-title":"J. Pharm. Pract."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Hall, V., Kwong, J., Johnson, D., and Ekinci, E.I. (2017). Caution Advised with Dapagliflozin in the Setting of Male Urinary Tract Outlet Obstruction. BMJ Case Rep., 2017.","DOI":"10.1136\/bcr-2017-219335"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/jgid.jgid_276_21","article-title":"Characteristics of Bacterial Colonization and Urinary Tract Infection after Indwelling of Double-J Ureteral Stent and Percutaneous Nephrostomy Tube","volume":"14","author":"Kar","year":"2022","journal-title":"J. Glob. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.urology.2018.03.042","article-title":"Urinary Tract Infections after Urinary Diversion\u2014Different Occurrence Patterns in Patients with Ileal Conduit and Orthotopic Neobladder","volume":"116","author":"Mano","year":"2018","journal-title":"Urology"},{"key":"ref_50","first-page":"83","article-title":"Failure of SGLT-2 Inhibitor in the Context of New Ileal Conduit Formation","volume":"136","author":"Gupta","year":"2023","journal-title":"N. Z. Med. J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"gfad063c_6212","DOI":"10.1093\/ndt\/gfad063c_6212","article-title":"#6212 Severe Hyperchloremic Metabolic Acidosis with SGLT-2 Inhibitors in Patients with Urinary Diversion","volume":"38","author":"Cruz","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ijid.2020.06.073","article-title":"Candida Sepsis from Local Infection in a Patient with a Urostomy on SGLT2 Inhibitor Therapy","volume":"98","author":"Wendt","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_53","first-page":"11289","article-title":"Effect of Obesity and Hyperglycemia on Benign Prostatic Hyperplasia in Elderly Patients with Newly Diagnosed Type 2 Diabetes","volume":"8","author":"Chen","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ijcard.2009.03.099","article-title":"An Insidious Risk Factor for Cardiovascular Disease: Benign Prostatic Hyperplasia","volume":"144","author":"Karatas","year":"2009","journal-title":"Int. J. Cardiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e2343299","DOI":"10.1001\/jamanetworkopen.2023.43299","article-title":"Cardiovascular Outcomes of \u03b1-Blockers vs 5-\u03b1 Reductase Inhibitors for Benign Prostatic Hyperplasia","volume":"6","author":"Zhang","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Podest\u00e0, M.A., Sabiu, G., Galassi, A., Ciceri, P., and Cozzolino, M. (2023). SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020279"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction","volume":"143","author":"Jhund","year":"2020","journal-title":"Circulation"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"i137","DOI":"10.1093\/eurheartjsupp\/suae117","article-title":"SGLT2 Inhibitors and New Frontiers in Heart Failure Treatment Regardless of Ejection Fraction and Setting","volume":"27","author":"Merlo","year":"2024","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"123192","DOI":"10.1016\/j.lfs.2024.123192","article-title":"Association between Metabolic Syndrome and Benign Prostatic Hyperplasia: The Underlying Molecular Connection","volume":"358","author":"Fu","year":"2024","journal-title":"Life Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00345-021-03817-z","article-title":"Benign Prostatic Hyperplasia and Cardiovascular Risk: A Prospective Study among Chinese Men","volume":"40","author":"Wang","year":"2021","journal-title":"World J. Urol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"102563","DOI":"10.1016\/j.jiac.2024.11.013","article-title":"Identification of Causative and Non-Causative Microorganisms of Nephrostomy Tube-Associated Pyelonephritis among Patients with Malignancy","volume":"31","author":"Terada","year":"2024","journal-title":"J. Infect. Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0022-5347(17)61547-7","article-title":"Bacterial Flora of Urine from Ileal Conduit","volume":"105","author":"Bishop","year":"1971","journal-title":"J. Urol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e1523","DOI":"10.1002\/wsbm.1523","article-title":"Fluid Mechanical Modeling of the Upper Urinary Tract","volume":"13","author":"Zheng","year":"2021","journal-title":"WIREs Mech. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1148\/85.2.338","article-title":"Dynamics of Ileal Conduits","volume":"85","author":"Campbell","year":"1965","journal-title":"Radiology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ajic.2003.08.005","article-title":"Role of Biofilm in Catheter-Associated Urinary Tract Infection","volume":"32","author":"Trautner","year":"2004","journal-title":"Am. J. Infect. Control"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1016\/j.jvir.2023.12.392","article-title":"Abstract No. 345 An Analysis of Biofilm Formation in Indwelling Percutaneous Nephrostomy Catheters","volume":"35","author":"Savidge","year":"2024","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_69","unstructured":"Bagley, B., Tan, C.L., and Plante, D. (2025, April 27). When Taking an SGLT2 Inhibitor, Remember to SSTOP (Stop SGLT2 Inhibitor Three Days before Procedures)! WebM&M: Case Studies [Internet], Available online: https:\/\/psnet.ahrq.gov\/webmm\/case\/460."},{"key":"ref_70","first-page":"e15533","article-title":"Postoperative Euglycemic Ketoacidosis in Type 2 Diabetes Associated with Sodium-Glucose Cotransporter 2 Inhibitor: Insights Into Pathogenesis and Management Strategy","volume":"13","author":"Chandrakumar","year":"2021","journal-title":"Cureus"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Kuo, I.-C., Lee, J.-J., Hwang, D.-Y., Lim, L.-M., Lin, H.Y.-H., Hwang, S.-J., Chen, H.-C., and Hung, C.-C. (2020). Pyuria, Urinary Tract Infection and Renal Outcome in Patients with Chronic Kidney Disease Stage 3\u20135. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-76520-5"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Confederat, L.-G., Dragostin, O.-M., and Condurache, M.-I. (2025). SGLT2 Inhibitors and the Risk of Urogenital Infections: A Concise Review. J. Clin. Med., 14.","DOI":"10.3390\/jcm14061960"},{"key":"ref_74","unstructured":"U.S. Food and Drug Administration (2025, April 27). FDA Warns About Rare Occurrences of a Serious Infection of the Genital Area with SGLT2 Inhibitors for Diabetes. FDA Safety Communication [Internet], Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Gorgojo-Mart\u00ednez, J.J., G\u00f3rriz, J.L., Cebri\u00e1n-Cuenca, A., Conde, A.C., and Arribas, M.V. (2024). Clinical Recommendations for Managing Genitourinary Adverse Effects in Patients Treated with SGLT-2 Inhibitors: A Multidisciplinary Expert Consensus. J. Clin. Med., 13.","DOI":"10.3390\/jcm13216509"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.2337\/dc21-1917","article-title":"Sodium\u2013Glucose Cotransporter 2 Inhibitors and Risk of Bladder and Renal Cancer: Scandinavian Cohort Study","volume":"45","author":"Ueda","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.34067\/KID.0000732021","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Transplantation: What Are We Waiting For?","volume":"2","author":"Patel","year":"2021","journal-title":"Kidney360"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1056\/NEJMicm2114684","article-title":"Fungal Ball in the Urinary Bladder","volume":"387","author":"Chang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Mathiasen, A.S.F., Andersen, M.F.B., Antsupova, V., and Fode, M. (2024). \u2018Case of the Month\u2019 from Herlev and Gentofte Hospital, Denmark: Candidaemia and Fungus Ball in a Patient with Diabetes on Sodium-glucose Co-transporter 2 Inhibitor. BJU Int.","DOI":"10.1111\/bju.16466"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"zwae175.061","DOI":"10.1093\/eurjpc\/zwae175.061","article-title":"Effects of Urinary Tract Infection and Stopping Sodium-Glucose Cotranspoter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Population-Based Study","volume":"31","author":"Wu","year":"2024","journal-title":"Eur. J. Prev. Cardiol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/5\/921\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:35:34Z","timestamp":1760031334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/5\/921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":80,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["medicina61050921"],"URL":"https:\/\/doi.org\/10.3390\/medicina61050921","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]}}}